Apostolova, Liana G.Haider, Janelle M.Goukasian, NairaRabinovici, Gil D.Chetelat, GaelRingman, John M.Kremen, SarahGrill, JoshuaRestrepo, LucasMendez, Mario F.Silverman, Daniel H.2017-05-012017-05-012016-12-18Apostolova, L. G., Haider, J. M., Goukasian, N., Rabinovici, G. D., Chételat, G., Ringman, J. M., … Silverman, D. H. (2016). Critical review of the Appropriate Use Criteria for amyloid imaging: Effect on diagnosis and patient care. Alzheimer’s & Dementia : Diagnosis, Assessment & Disease Monitoring, 5, 15–22. http://doi.org/10.1016/j.dadm.2016.12.001https://hdl.handle.net/1805/12391INTRODUCTION: The utility of the Appropriate Use Criteria (AUC) for amyloid imaging is not established. METHODS: Fifty-three cognitively impaired patients with clinical F18-florbetapir imaging were classified as early and late onset, as well as AUC-consistent or AUC-inconsistent. Chi-square statistics and t test were used to compare demographic characteristics and clinical outcomes as appropriate. RESULTS: Early-onset patients were more likely to be amyloid positive. Change in diagnosis was more frequent in late-onset cases. Change in therapy was more common in early-onset cases. AUC-consistent and AUC-inconsistent cases had comparable rates of amyloid positivity. We saw no difference in the rate of treatment changes in the AUC-consistent group as opposed to the AUC-inconsistent group. DISCUSSION: The primary role of amyloid imaging in the early-onset group was to confirm the clinically suspected etiology, and in the late-onset group in detecting amyloid-negative cases. The rate of therapeutic changes was significantly greater in the early-onset cases.en-USAttribution-NonCommercial-NoDerivs 3.0 United StatesAlzheimer's disease (AD)AmyloidAppropriate use criteria (AUC)Mild cognitive impairment (MCI)Positron emission tomography (PET)Article